Council Members
President
Dr. Alexander Vinks
Alexander
(Sander) Vinks is Professor of Pediatrics and Pharmacology (Adj.) at
the University of Cincinnati, Colleges of Medicine and Pharmacy. He is
the director of the Division of Clinical Pharmacology, principal
investigator of the NIH Pediatric Pharmacology Research Unit at
Cincinnati Children’s and Director of the Laboratory of Applied
Pharmacokinetics and Therapeutic Drug Management. Dr. Vinks received
his pharmacy and pharmacology training at Leiden University and the
University of Toronto, Canada. He received specialty training in
clinical pharmacy (PharmD) and clinical pharmacology (PhD) at The Hague
Hospitals Central Pharmacy and Leiden University in the Netherlands.
Dr. Vinks is board certified in Clinical Pharmacology and Toxicology.
Before joining the Division of Clinical Pharmacology at Cincinnati
Children’s in 2000, he was Director of the centralized Clinical
Pharmacology & Toxicology Laboratory for the city of The Hague. His
major research interests include pharmacokinetic-pharmacodynamic
(PK/PD) modeling, pharmacogenetics (PG) and the application of genomic,
population and simulation approaches (Pharmacometrics) to clinical
trial design, Therapeutic Drug Monitoring (TDM) and individualized
Bayesian dosing strategies. His current research includes the
development of biomarker assays for the measurement of pharmacodynamic
effects of immunosuppressive drugs. Dr. Vinks has ongoing NIH funding
to further advance PK/PD/PG modeling and simulation in pediatric
patients with a focus in optimizing immunosuppressive and antimicrobial
therapies. He is directing several clinical pharmacology cores for
ongoing multi-center clinical studies evaluating target controlled
therapies using population model-based approaches. Dr. Vinks has
received several distinctions for his research, including the Huizinga
Award for Research in Hospital Pharmacy from the Netherlands. Dr. Vinks
is president-elect of the International Association of Therapeutic Drug
Monitoring and Clinical Toxicology. He is chairing the Therapeutic
Monitoring and Toxicology (THE) scientific section of the American
Society of Clinical Pharmacology and Therapeutics (ASCPT) and is a
fellow of the American College of Clinical Pharmacology. He is on the
Editorial Board of Antimicrobial Agents and Chemotherapy, Clinical
Therapeutics, Therapeutic Drug Monitoring, Journal of Pediatric
Pharmacology and Therapeutics, and the Journal of Clinical Medicine
(Bulgaria). Dr. Vinks is an internationally renowned speaker with more
than 140 presentations at national and international meetings. He has
authored over 70 peer-reviewed publications and 14 book chapters and
reviews in the areas of PK/PD modeling, pharmacogenetics and TDM.
Dr. Alexander A. Vinks
Professor of Pediatrics
Cincinnati Children’s Hospital and Medical Center
MLC 6018, Oak South Room 2529
3333 Burnet Avenuen
Cincinnati OG 45229-3039
USA
Sander.vinks@chmcc.org
President-Elect
Prof. Pierre Marquet
Pierre Marquet has been a Doctor of Medicine since 1986 and obtained a master in statistics and epidemiology followed by a PhD in physiology in 1992. After several years as a toxicologist at Limoges University Hospital, he has been an associate professor of pharmacology since 1998 and in 2001, became a full professor at the Faculty of Medicine of Limoges, France. He is head of the “Clinical PK and TDM” unit and of “Clinical research in TDM and toxicology” at the University Hospital of Limoges. He is also the Director of the INSERM U850 research unit called “Pharmacology of immunosuppressive drugs in transplantation” (INSERM is the French Institute of Medical and Health Research).
He conducts translational research on treatment personalization, mainly concerning immunosuppressants (IS) in organ transplantation, which covers: new analytical methodologies for IS; metabolic and pharmacogenetic studies of the IS; application to population pharmacogenetic-pharmacokinetic analysis and therapeutic drug monitoring; and epidemiological studies and clinical trials in transplant patients.
He has published over 120 papers in peer-reviewed, international journals.
Dr. Pierre Marquet
Pharmacology & Toxicology
University Hospital
2 av Martin Luther King
Limoges Cedex 87042
France
Pierre.marquet@unilim.fr
Past President
Prof. Dr.Dr. h.c. Hans H. Maurer
Hans
H. Maurer is full Professor of Pharmacology & Toxicology at the
Faculty of Medicine and at the Faculty of Pharmacy, University of
Saarland, since 1992. He is head of the Department of Experimental and
Clinical Toxicology. His main two areas of research are analytical
toxicology (GC-MS, LC-MS of drugs, poisons and their metabolites) and
in-vitro and in-vivo metabolism (phase I and phase II, isoenzyme
identification, pharmacogenetics). He has published extensively in both
areas (besides original papers, reviews and proceedings, handbooks and
computer databanks on GC-MS).
He is editorial board member of the Journal of Chromatography B,
Therapeutic Drug Monitoring, Analytical and Bioanalytical Chemistry,
Current Pharmaceutical Analysis, Current Drug Metabolism, Drug
Metabolism Letters, Annales Pharmaceutiques Françaises, SUCHT - German
Journal of Addiction Research and Practice, and reviewer of most of the
international journals of his field as well as of scientific research
foundations in Germany, UK, Switzerland, and New Zealand. He was guest
editor of special issues of Journal of Chromatography B (1998),
Therapeutic Drug Monitoring (2002 and 2004) and Analytical and
Bioanalytical Chemistry (2007).
In his career, Dr. Maurer received several scientific awards, among
which the Young Investigator Award of the Medical Faculty presented in
Homburg 1983, the Irving Sunshine Award for Outstanding Contributions
to Clinical Toxicology of the International Association of Therapeutic
Drug Monitoring and Clinical Toxicology (IATDM-CT) presented in
Vancouver 1997, "Membre d'Honneur" de la Société Française de
Toxicologie Analytique (SFTA) presented in Dinard 2003, and finally the
Alan Curry Lifetime Achievement Award of TIAFT for Outstanding
Contributions to Forensic Toxicology presented in Melbourne 2003. In
2007, he received the Doctor honoris causa degree of the University of
Ghent in Belgium for his outstanding scientific achievements.
Besides his membership in several national and international scientific
societies, Dr. Maurer is President of the International Association of
Therapeutic Drug Monitoring and Clinical Toxicology (IATDM-CT,
2007-2009) and is TIAFT executive board member (2005-2011), treasurer
of the Society of Toxicological and Forensic Chemistry (GTFCh, since
1987), chairman of the GTFCh Committee "Clinical Toxicology", since
1997, and finally chapter president of Saarland of the German
Pharmaceutical Society (DPhG, 2004-2006).
Professor Dr. Dr. h.c. Hans H. Maurer
Head, Department of Experimental and Clinical Toxicology
Institute of Experimental and Clinical Pharmacology and Toxicology
Saarland University, D-66421 Homburg/Saar (Germany)
e-mail: hans.maurer@uks.eu
web: http://wwwalt.med-rz.uniklinik-saarland.de/med_fak/pharma-toxi/Seiten/Maurer_frame.html
Secretary
Dr. Donald LeGatt
Dr.
LeGatt is a Clinical Biochemist who has been head of the Clinical Toxicology
and Therapeutic Drug Monitoring Laboratory at University of Alberta Hospital,
Edmonton for twenty eight years. He is a Clinical Professor at the University
of Alberta with teaching responsibilities in the Faculty of Medicine and
Dentistry and has been a Consultant Toxicologist at DynaLIFE, Edmonton for eleven and a
half years. His actual “roots” are in Pharmacy, having obtained both his
Bachelor’s and Ph.D degrees in the discipline. He has been a Member of IATDMCT
since 1990, and has previously served as a Councilor and Director of Education.
He has also served on the organizing Committees of three Congresses. Dr. LeGatt
is a Founding Fellow of the Canadian Academy of Clinical Biochemistry (CACB), and
has been a member of the Canadian Society of Clinical Chemists (CSCC) and the
American Association of Clinical Chemistry (AACC) since 1983. He has also served
three terms as President of the Alberta
Society for Human Toxicology (ASHT). He has received several awards: a Capital Health “Esprit de Corps”
Recognition Award in 1997; a CSCC International Visitor Award in 2001; in 2005,
the Certificate for Meritorius Service from the College of Physicians and
Surgeons of Alberta, the CSCC Education Excellence Award and a Capital Health
Reach Award for Innovation Excellence; in 2006, an “Outstanding Speaker Award”
from AACC; in 2008, a City of Spruce Grove Award of Excellence for Innovation
and a CSCC Best Poster Award; in 2009,
the “Teacher of the Year Award” in Clinical Pathology, University of
Alberta. He is an avid proponent of progressive, rational clinical toxicology
testing. Dr. LeGatt’s research interests span the areas of toxicokinetics,
applied pharmacokinetics and method development. He has over 100 publications,
abstracts and book articles to his credit.
Treasurer
Dr. Loralie Langman
Loralie
Langman, Ph.D. got her BSc in Laboratory Medicine and Pathology, CSMLS,
and ASCP certifications at the University of Alberta and University of
Alberta Hospital. After working for a few years as a laboratory
technologist, she then went back to school and completed her Ph.D. in
Medicine – Laboratory Medicine and Pathology at the University of
Alberta. She completed her Clinical Chemistry training at the
University of Toronto, specializing in Forensic Toxicology and
Molecular Genetics. Prior to coming to Mayo Clinic Rochester, she was
in Vancouver, British Columbia, at the Provincial Toxicology Centre and
BC Biomedical Laboratories as a Forensic Toxicologist/Clinical Chemist.
Dr. Langman was certified with the Canadian Academy of Clinical
Biochemistry (CACB) and is the first individual to have achieved
Diplomat status with the American Board of Clinical Chemistry (ABCC) in
all three disciplines (Clinical Chemistry, Molecular Diagnostics, and
Toxicological Chemistry). She is also a Diplomat with the American
Board of Forensic Toxicology. Dr. Langman is a member of and serves on
committees for several professional organizations including: The
Society of Forensic Toxicologists; the American Academy of Forensic
Sciences; the National Academy of Clinical Biochemistry; the American
Association for Clinical Chemistry; the Canadian Society of Clinical
Chemists; the International Association of Therapeutic Drug Monitoring
and Clinical Toxicology; and The International Association of Forensic
Toxicologists. Currently, Dr. Langman is Director of the Toxicology and
Drug Monitoring Laboratory at Mayo Clinic Rochester. She has over 30
publications and over 40 abstracts/presentations at National and
International meetings. Her areas of expertise include: toxicology;
drugs of abuse (particularly amphetamine-type stimulants and cocaine);
post-mortem toxicology; therapeutic drug management; and
pharmacogenetics. Her current research interests include metabolism and
pharmacogenomics of amphetamine-type stimulants and cocaine; and
genotype phenotype relationships of psychoactive medications.
Dr. Loralie J. Langman
Toxicology and Drug Monitoring Laboratory
Mayo Clinic Hilton 210E
200 First Street SW
Rochester MN 55905
USA
langman.loralie@mayo.edu
Directors of Education
Dr. Vanessa Steenkamp
Vanessa Steenkamp is Professor of Pharmacology at the
University of Pretoria, South Africa.
She is a Senior Lecturer and heads the Phytopharmacology Unit. Prof Steenkamp obtained her PhD
in Clinical Chemistry specializing in clinical toxicology at the University of
the Witwatersrand. She is
registered with the Health Professional Council of South Africa as well as the
South African council for Natural Scientific Professions. Her research focus is
the determination of biological activity of traditional herbal remedies in
order to identify compounds with pharmacological activity, which can be
developed as new agents in treatment of diseases. Prof Steenkamp is the author and co-author of 56 scientific
papers. She has received numerous
awards for her research both nationally and internationally. She is the
President of the South African Association of Clinical Biochemists,
Vice-President of the Toxicology Society of South Africa, Secretary-General of
the South African Association of Basic and Clinical Pharmacology, Treasurer of
the Federation of the South African Society of Pathologists. Internationally, Vanessa serves as
steering member of the Committee for Congresses & Conferences on the IFCC
and as Director of Education and Committee member of the Clinical Toxicology
Committee of the IATDMCT. She is
the National representative for Clinical Chemistry in South Africa to the
International Federation of Clinical Chemistry. She was recently selected first President of the
African Federation of Clinical Chemistry. She serves as reviewer for 14
journals as well as research proposals for funding bodies and is on the
editorial board of two journals. She has 149 conference contributions and has
been the invited speaker on 14 occasions.
Dr. Teun Van Gelder, MD, PhD
Dr. Teun van Gelder is an internist and clinical pharmacologist in the Department of Hospital Pharmacy at the Erasmus Medical Center in Rotterdam, the Netherlands. He was trained in internal medicine and nephrology at the Erasmus Medical Center, and completed his thesis in 1996 on the use of anti-interleukin-2 receptor monoclonal antibodies in solid organ transplantation. As a post-doctoral scientist, he worked in the Transplantation Immunology Laboratory of Dr. Randall E. Morris at Stanford University, and was awarded the Young Investigator Award from the American Society for Transplantation for his work during this time. Dr. van Gelder’s current research at the Erasmus Medical Center is focused on clinical pharmacology and therapeutic drug monitoring.Dr. Teun Van Gelder, MD, PhD
Internist
Erasmus Medical Center
Molewaterplein 40
Rotterdam 3015 GD
The Netherlands
t.vangelder@erasmusmc.nl
Dr. Pierre Wallemacq
Pierre Wallemacq is Professor at the Université catholique de Louvain, Medical school in Brussels, Belgium. He teaches clinical chemistry, toxicology and clinical pharmacokinetics, and is the vice president of the biomedical sciences school. He is responsible of a research unit (LBCM) in the Medical School and supervises several PhD theses. He is also head of laboratory in the Cliniques universitaires St Luc, Brussels, in charge of the analytical biochemistry platform regrouping activities such as TDM, clinical toxicology, forensic toxicology, but also special chemistry (GC, HPLC, UPLC, LC-MSMS, GC-MS etc…). He started working in the field of TDM since 1982 with his PhD thesis on cyclosporine, and is author or coauthor of more than 110 manuscripts with peer-reviews and several chapters of textbooks. Most of his work was dedicated to immunosuppressive drugs, but he also published works in other clinical chemistry of TDM/TOX areas. Pierre Wallemacq has been elected president of the Royal Belgian Society of Clinical Chemistry (SBCC-BVKC) in 2008, and president of the Belgian and Luxemburg society of Toxicology (BLT) in 2007. He is member of the Editorial Boards of several International Journals such as Therapeutic Drug Monitoring (TDM), Clinical Biochemistry (CLB), Clinical Chemistry and Laboratory Medicine (CCLM). He has been involved as member of the scientific organization committees of several international congresses.
Prof. Pierre Wallemacq
Dept. of Clinical Chemistry
University Hospital St. Luc
Av. Hippocrate 10
B-1200 Bruxelles 1200
Belgium
Councillors
Dr. William Clarke, USA
Dr. Clarke received his Ph.D. in
Analytical Chemistry from the University of Nebraska in Lincoln in 2000,
followed by a post-doctoral fellowship in Clinical Chemistry at the Johns
Hopkins School of Medicine, ending in 2002. In addition, he received an MBA focused on medical services
management from the Carey School of Business at Johns Hopkins in 2007. Following his post-doctoral fellowship,
he has remained at Johns Hopkins, where he is an Assistant Professor in the
Department of Pathology, as well as the director of both Point-of-Care Testing
and TDM/Toxicology for the hospital.
Dr. Clarke is board certified in Clinical Chemistry by the American
Board of Clinical Chemistry, and is a Fellow of the National Academy of Clinical
Biochemistry. His research
interests include method development and evaluation for TDM, pharmacogenomics, pharmacoproteomics,
and the study of outcomes and medical decision-making in the context of
variability in laboratory measurements.
Dr. Clarke has published 30 papers in journals such as Analytical Chemistry, Journal of Chromatography, Clin Chim Acta, and Annals of Surgery, as well as 24 book chapters. He is a co-editor of the book Contemporary Practice in Clinical Chemistry, and is currently the sole editor for the second edition of that book. Dr. Clarke was the recipient of the 2004 George Grannis Award from the NACB for excellence in research and publication by a young investigator, and also the 2005 AACC TDM/Toxicology Division Young Investigator Award.
Dr. Mercè Brunet (Spain)
Dr. Frank T. Peters (Germany)
Frank T. Peters was born in Trier, Germany, in
1971, where he also went to elementary school and high school. He started
studying pharmacy at the Johann-Wolfgang-Goethe University in Frankfurt/Main,
Germany, in 1993 and obtained the licence to practice as a pharmacist in 1998.
Thereafter, he started working as a research
assistant and PhD student of Prof. Dr. Dr. h.c. Hans H. Maurer at the
Department of Experimental and Clinical Toxicology of the Saarland University in
Homburg, Germany, where he finished his PhD thesis in June of 2003. From then to
the end of 2008 he worked in the same department as a post-doc and deputy of
Prof. Maurer. In June 2009 he finished his habilitation (licence to lecture at
the university) in the field of pharmacology and toxicology at the Medical
Faculty of the Saarland University. Since 2009 he is the Head of Forensic and
Clinical Toxicology at the Institute of Forensic Medicine at the University
Hospital in Jena, Germany.
The main research interests of Frank T. Peters
are biotechnological synthesis of drug metabolites, enantioselective analysis
of amphetamines and amphetamine-like designer drugs, analysis of new designer
drugs in blood samples, metabolism of drugs and poisons, determination of
sedating drugs in the context of declaration of brain death, and experimental
designs and statistical procedures for analytical method validation.
Frank T. Peters is author or co-author of 59 peer-reviewed
publications, one book and six book chapters. He is a member of The International Association of Forensic
Toxicologists (TIAFT), the German
Pharmaceutical Society (DPhG), the Society
of Toxicological and Forensic Chemistry (GTFCh), and of the International Association of Therapeutic
Drug Monitoring &Clinical Toxicology (IATDMCT). Frank T. Peters is chairman
of IATDMCT’s and TIAFT’s Young Scientist Committees.
Dr. Benedetta Salustio (Australia)
Dr Sallustio was awarded her PhD in 1990 from
Flinders University in South Australia. She is currently Principal Medical
Scientist in the Department of Clinical Pharmacology at The Queen Elizabeth
Hospital, and Affiliate Associate Professor in the Discipline of Pharmacology
at the University of Adelaide, in South Australia.
Dr Sallustio’s area of research interests include
drug metabolism and transport, particularly understanding how inter-individual
differences in these processes, either genetic or environmental, impact on drug
toxicity and clinical efficacy. She has pursued three main arms of research: i)
the role of metabolism in enhancing drug toxicity, particularly intracellular
protein and genetic damage; ii) applying an understanding of metabolic pathways
and their genetic variability to enhance the clinical use of the anti-anginal
agent perhexiline; and iii) applying an understanding of variability in the
metabolism and cellular transport of immunosuppressants to improving clinical
outcomes in renal transplant recipients. This work has been supported by major
competitive funding from the National Heart Foundation, the Anti Cancer
Foundation, the National Health and Medical Research Council, and the Juvenile
Diabetes Research Foundation, and has resulted in 60 peer-reviewed publications
in international journals and 103 presentations at national and international
scientific meetings.
Dr Sallustio is a member of a number of national and
international scientific societies and currently serves as Convenor of the
Adelaide Pharmacology Group, is on the Scientific Advisory Committee of the
Australasian Society of Clinical and Experimental Pharmacologists and
Toxicologists (since 2007), and is an elected Councillor of the International
Association of Therapeutic Drug Monitoring and Clinical Toxicology (2009-2011).
Department of Clinical Pharmacology
The Queen Elizabeth Hospital, Basil Hetzel Institute
28 Woodville Road
Woodville SA 5011 Australia
benedetta.sallustio@health.sa.gov.au
